TRASTUZUMABE DERUXTECANA/PROs T-DXd
EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER TREATED WITH TRASTUZUMAB DERUXTECAN IN THE ONCOCLINIS GROUP
Biomarker: HER+
Inclusion criteria
Female or male patients with HER+ metastatic malignancy of the breast who will start treatment with T-DXd; Age greater than 18 years.
Exclusion criteria
Use of other concomitant antineoplastic therapies;
Patients for whom the physician responsible for prescribing T-DXd is from an institution other than the Oncoclínicas Group.
Clinical research
Check out more information about Grupo Oncoclínicas' clinical research program.
Learn more
